REC Ref No.	IRAS No.	Name of Trial	Date First	Date Site	Date Site	HRA Approval	Date Site	Date Site	Non-	Date Site	Reasons for
			Participant Recruited	Invited	Selected	Date	Confirmed By Sponsor	Confirmed	Confirmation Status	Ready To Start	delay correspond to:
			Recruited				Sponsor		Status		to.
21/NI/0032	1003609	A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF		08/03/2021	24/03/2021						
		ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS LENVATINIB OR SORAFENIB ALONE IN									
		HEPATOCELLULAR CARCINOMA PREVIOUSLY									
		TREATED WITH ATEZOLIZUMAB AND BEVACIZUMAB									
20/HRA/6152	292509	The LAVA (Lateral flow Antigen Validation and Applicability) 2 Study for COVID-19			23/03/2021						
21/EE/0039	290104	A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL,		09/02/2021	12/02/2021						
		ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (T-DXd) VERSUS TRASTUZUMAB									
		EMTANSINE (T-DM1) IN SUBJECTS WITH HIGH-RISK									
		HER2-POSITIVE PRIMARY BREAST CANCER WHO HAVE									
		RESIDUAL INVASIVE DISEASE IN BREAST OR AXILLARY LYMPH NODES FOLLOWING NEOADJUVANT THERAPY									
		ETWINTINGEST SEESWING NEGABOOVANT THEIRA									
21/SC/0084	293797	A Phase 3 Randomized, Double-Blind, Placebo-Controlled,		05/03/2021	05/03/2021						
		Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced									
		Kidney Function who are Hospitalized for COVID-19									
04/11/20400	004400	OOTAV/F. Olivery street Outlette Tiel. The He Australian		47/00/0004	05/00/0004		00/00/0004	00/00/0004		40/00/0004	
21/HRA/0489	294480	OCTAVE: Observational Cohorts Trial - T-cells Antibodies and Vaccine Efficacy in SARS-CoV-2		17/02/2021	05/03/2021		09/03/2021	09/03/2021		10/03/2021	
20/WS/0171	281799	Physiologic Pacing Registry		28/01/2021	08/02/2021						
19/WS/0107	256189	A pivotal study of derazantinib in patients with inoperable or			02/03/2021						
		advanced intrahepatic cholangiocarcinoma and FGFR2 gene fusions or FGFR2 gene mutations or amplifications									
21/ES/0006	282284	ELEVATE: Temozolomide + nivolumab in MGMT deficient		25/01/2021	25/01/2021						
		oesophagogastric cancer									
20/EE/0254		AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS			20/01/2021	20/01/2021		31/03/2021			Neither
		CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY									
		VERSUS STANDARD OF CARE THERAPY WITH A									
		SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB									
		PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL									
		CANCER									
21/SC/0017	268864	MultiStemÃ,® Administration for Stroke Treatment and		03/03/2021	03/03/2021						
20/SC/0377	287169	Enhanced Recovery Study Recombinant Factor VIIa for Acute Hemorrhagic Stroke		03/03/2021	03/03/2021						
20/30/03//	207 109	Administered at Earliest Time (FASTEST) Trial		03/03/2021	03/03/2021						

					1				
20/HRA/6338	293815	A randomised, multicentre post-exposure prophylaxis (PEP)	13/01/202	1 19/02/2021			15/03/2021		
		clinical trial evaluating RESP301, an inhaled therapy for							
		treatment of lung infections, for prevention of onward							
		transmission of viral infections including SARS-CoV-2 to							
20/EE/0252	276415	household members.	11/12/202	0 18/12/2020	20/01/2021		07/04/2021		Neither
20/EE/0252	2/04/15	Pharmacological management of seizures post traumatic	11/12/202	.0 16/12/2020	20/01/2021		07/04/2021		Neither
	291949	brain injury A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm,	14/12/201	0 03/03/2021					
	291949	216 Week Study to Evaluate Efficacy and Safety of	14/12/202	.0 03/03/2021					
		Treatment With BAN2401							
		in Subjects With Preclinical Alzheimer's Disease and							
		Elevated Amyloid (A45 Trial) and in Subjects With Early							
		Preclinical Alzheimer's Disease and Intermediate							
		Amyloid (A3 Trial)							
20/NW/0383	287807	A Phase 3 Randomized, Double-Blind Placebo-Controlled	24/12/202	0 02/01/2021		16/02/2021	16/02/2021	26/02/2021	Sponsor
		Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-							
		5734TM) Treatment of COVID-19 in an Outpatient Setting							
19/EE/0377	266504	Trial of Ondansetron as a Parkinson's HAllucinations		01/02/2021			08/04/2021		
		Treatment							
20/SC/0111	276734	A Multicenter, Open-Label, Randomized Phase III Study to	27/11/202	0 07/12/2020		01/04/2021	12/04/2021		Sponsor
		Evaluate the Efficacy and Safety of the Combination of							
		Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-							
		Vd) Compared with the Combination of Daratumumab,							
		Bortezomib and Dexamethasone (D-Vd) in Participants with							
00/10/4070	000500	Relapsed/Refractory Multiple Myeloma	20/44/00	0. 0.7/4.0/0.000	00/04/0004	00/04/0004	00/00/0004		N1 2/1
20/LO/1278	288502	A multicenter, Phase 2a, open-label, non-randomized	26/11/202	07/12/2020	26/01/2021	28/01/2021	02/02/2021		Neither
		study evaluating the efficacy, safety, and tolerability of BIVV020 in adults with persistent/chronic immune							
		thrombocytopenia (ITP)-PDY16894							
20/NW/0300	285728	A Phase 3, randomized, double-blind, efficacy and safety	23/11/202	0 14/12/2020	15/09/2020				Neither
20/11/1/	200720	study comparing SAR442168 to placebo in participants with	20/11/202	14/12/2020	10/03/2020				Nottrior
		nonrelapsing secondary progressive multiplesclerosis							
		(HERCULES)							
20/SW/0186	290807	INTERVENTION 1 PROTOCOL (Xarelto): A randomized,	04/12/202	0 08/12/2020		11/01/2021	12/01/2021		Neither
		controlled, Phase 2b study to evaluate safety and efficacy of							
		rivaroxaban (Xarelto®) for high risk people with mild COVID-							
		19							
20/LO/1291	292074	The effect of semaglutide in subjects with non-cirrhotic non-	03/12/202	02/03/2021		17/03/2021	13/04/2021		
21/1/2/2222		alcoholic steatohepatitis	27/1/20	/ / /					
21/LO/0203	288725	ORBITA-COSMIC: Coronary sinus reducer Objective impact	25/11/202	0 09/03/2021	27/03/2021				
		on Symptoms, MRI Ischaemia and microvascular Resistance							
20/LO/1129	1003422	A Phase 2 study to evaluate the safety and efficacy of		05/02/2021					
20,20,1120		EP0057 in combination with Olaparib in advanced ovarian		33,02,2021					
		cancer patients who have: Cohort 1 – platinum resistant							
		disease and are PARP inhibitor naà ve; Cohort 2 – had at							
		least 2 prior lines of therapy which must include at least 1							
		line of platinum-based chemotherapy followed by PARP							
		inhibitor maintenance.							
	•			•			•	*	

20/WM/0297	288227	A Phase 3, Open-label, Single Arm, Multicenter Study of	09/11/2	20 23/03/2021						
		Ravulizumab in Addition to Best Supportive Care in Pediatric								
		Participants (from 1 month to < 18 years of age) with								
		Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)								
20/NI/0070	1003313	Brain Re-Irradiation Or Chemotherapy: a phase II	07/10/2	20 09/03/2021	07/07/2020					
		randomised trial of re-irradiation and chemotherapy in								
		patients with recurrent glioblastoma								
20/WM/0195	268363	A multi-centre phase II trial of GVHD prophylaxis following	27/11/2	20 30/11/2020		05/03/2021	08/03/2021		17/03/2021	Sponsor
		unrelated donor stem cell transplantation comparing								
		Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based								
		post-transplant cyclophosphamide								
20/SC/0018	258872	A randomised controlled trial assessing if microsurgical nerve	07/10/2	20 25/11/2020	13/02/2020					Neither
		repair offers clinical benefit and cost effectiveness (in								
		terms of patient–reported hand function, sensory recovery								
		and adverse events) over exploration and washout without								
		microsurgical nerve repair in adult patients with recent								
		traumatic digital nerve injury.								
20/LO/1056	277635	Venetoclax or Intensive Chemotherapy for Treatment Of	13/10/2	20 12/11/2020		01/04/2021	06/04/2021			Neither
		Favourable Risk Acute Myeloid Leukaemia: A Molecularly								
		Guided Phase 2 Study								
20/NW/0463	1003437	Phase 2 Study of MK-6482 in Participants With Advanced		09/12/2020						Neither
// 0 / 2		Renal Cell Carcinoma	10/10/0			10/01/0001	17/2//2021		1 - 1 - 1 - 1 1	
21/LO/0051	285417	Diagnosis of Heart Failure in the Post-COVID-19 Clinic,	19/10/2	20 29/03/2021	05/02/2021	13/04/2021	15/04/2021		15/04/2021	
		Primary Care and Hospital Setting Using a Digital								
20/1-0/0040	004400	Stethoscope with AI ECG	40/40/2	20 20/02/2024	05/40/2020					
20/LO/0840	264482	Functional and Ultrasound guided Resection of Glioblastoma. A two stage trial. Stage 1 – Non-randomised	16/10/2	20 22/03/2021	05/10/2020					
		collaborative learning and evaluation phase of participating								
		centres (IDEAL Stage 2b study), followed by Stage 2 – A								
		Multicentre Phase III trial with 2 mechanistic substudies.								
		inditioentre i mase in that with 2 moontainstic substitutes.								
20/LO/0196	271343	PreOperative Endocrine Therapy for Individualised Care with	05/10/2	20 16/11/2020	08/07/2020					Neither
00/1 0/4457	004007	Abemaciclib		0.4/4.0/0.000						NI a itiba a a
20/LO/1157	281627	An open-label, randomized, controlled phase 3 study of		04/12/2020	1					Neither
		enfortumab vedotin in combination with pembrolizumab with								
		or without chemotherapy, versus chemotherapy alone in								
		previously untreated locally advanced or metastatic urothelial cancer								
20/LO/1106	286152	Phase 1b, Multicentre, Multiple Ascending Dose, Safety,	23/09/2	20 11/01/2021		05/02/2021	09/04/2021			Neither
20/20/1100	200102	Pharmacokinetic, andPharmacodynamic Study of	23/09/2	20 11/01/2021		03/02/2021	03/04/2021			Titolinoi
		Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-								
		grade Serous Ovarian Cancer (HGSOC) Patients								
18/NW/0644	248582	A prospective open label, pharmacokinetic study of an oral	24/09/2	20 05/11/2020			Site	declined to partic	cipate)	
		hydroxyurea solution in children with sickle cell anemia	- :: 35/2						- 1/	
	į .	nyaranyaraa aaraaan in amaran wiin siaka aaran ahama			1	<u> </u>	1			1

		T									
20/SC/0117	269627	A two-year, phase III randomized, double-blind, parallel-		27/10/2020	17/11/2020						Neither
		group, placebo-controlled trial to evaluate the safety,									
		efficacy, and tolerability of 300 mg s.c. Secukinumab versus									
		placebo, in combination with SoC therapy, in patients with									
		active Lupus Nephritis (SELUNE)									
19/EE/0384	275752	VenaSeal Spectrum: Global, Post-Market, Prospective, Multi-		01/09/2020	11/02/2021	06/04/2020					
		Center, Randomized Controlled Trial of the VenaSealâ,¢									
		Closure System vs. Surgical Stripping or Endothermal									
		Ablation (ETA) for the Treatment of Early and Advanced									
		Stage Superficial Venous Disease									
20/YH/0317	288552	A Randomized, Double-blind, Placebo-controlled Phase 3	30/11/2020	30/10/2020	30/10/2020		13/11/2020	16/11/2020		23/11/2020	
		Study to Assess the Efficacy and									
		Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-									
		mediated COVID-19 in Adults									
		Aged 18 Years and Older									
20/LO/0504	1003208	Randomised controlled trial of Gestational treatment with		16/09/2020	08/01/2021						Neither
		Ursodeoxycholic Acid compared to Metformin to Reduce									
2 1 12 2 12 2 2 1		effects of Diabetes mellitus			/ /						
21/SC/0094	289344	A phase I study to determine safety and immunogenicity of		16/03/2021	16/03/2021						
		the candidate COVID-19 vaccine ChAdOx1 nCoV-19									
		delivered by aerosol in healthy adult volunteers		. = / = 2 / = = =							
20/SW/0117	1003162	Randomized, Double-Masked, Active-Controlled, Phase 3		15/09/2020	06/11/2020	01/09/2020					Sponsor
		Study of the Efficacy and Safety of High Dose Aflibercept in									
		Patients With Neovascular Age-Related Macular									
000000	070000	Degeneration		00/44/0000	07/44/0000	0.4.14.0.10.000		0.4 (0.0 (0.0 0.4			N1 30
20/WA/0343		Transplant Renal Artery Stenosis Observation versus Stenting		26/11/2020	27/11/2020	21/12/2020		01/02/2021			Neither
20/LO/1272	287235	A prospective randomised extended pilot study of a directed			25/03/2021	25/03/2021		13/04/2021			
		psycho-educational tool to prevent psychological sequelae									
		following Paediatric Intensive Care admission									
20/LO/0009	263698	Observational cohort with embedded Randomised Controlled		24/08/2020	05/01/2021			09/02/2021			Neither
		trials to study pregnancy-Associated progression of Renal									
		Disease – A Feasibility Study of Dietary Nitrate (BEETroot									
		juice) to protect kidney function in pregnant women with									
00/00/0070		Chronic Kidney Disease		00/07/0000	4.4/2.2/2.2.2	4.4./2.2./2.2.2.2	0.7/0.0/0.004	00/04/0004		07/04/0004	A. 1. 1.1
20/SS/0072	255036	A Long-term Follow-up Study of Subjects With		30/07/2020	14/08/2020	11/09/2020	05/02/2021	06/04/2021		07/04/2021	Neither
		β-thalassemia or Sickle Cell Disease Treated with									
		Autologous CRISPR-Cas9 Modified Hematopoietic									
00 W00044	007040	Stem Cells (CTX001)			00/44/0000	0.4/4.4/00000		00/40/0000		40/40/0000	No.'then
	287610	Bioimpedence and Arterial function Monitoring at Birth and in Infants: the BAMBI study			26/11/2020	24/11/2020		09/12/2020			Neither
20/WA/0197	284509	Validation of PAT for pre-operative screening for OSA	08/10/2020	04/08/2020	25/08/2020		02/07/2020	21/09/2020		21/09/2020	
20/EE/0170	1003070	Multicenter, randomized, placebo controlled, double-blind,	05/01/2021	20/05/2020	17/09/2020	29/07/2020	13/11/2020	01/12/2020		09/12/2020	Sponsor
		parallel group, dose-finding Phase 2 study to evaluate the									
		efficacy and safety of BAY 2433334 in patients following an									
		acute myocardial infarction									

40/4/4/0400	040007	Oniversal estate of the Adult Formal - Assess Assessed	1	ı	07/04/0004	04/00/0040	<u> </u>		Г		No:thor
18/WA/0420	246637	Spironolactone for Adult Female Acne: A pragmatic			07/01/2021	04/02/2019					Neither
		multicentre double-blind randomised superiority trial to									
		investigate the clinical and cost-effectiveness of									
		spironolactone for moderate or severe persistent acne in									
00/1 0/4444		women		0.4.10=10.000	40/00/0004		10/01/0001	10/01/0001			
20/LO/1111	286572	Prospective Evaluation to Characterize the Realâ€World		21/07/2020	18/03/2021		13/04/2021	19/04/2021			
		PerFormance of the EMBOVACTM Aspiration									
		Catheter for Neurothrombectomy: A Postâ€Market Clinical									
		Followâ€up Trial.									
20/EM/0003	269023	Multicentre, open-label, randomised controlled trial of early	13/12/2020	14/07/2020	14/07/2020		24/11/2020	02/12/2020		07/12/2020	Sponsor
		surfactant therapy									
		versus expectant management in late preterm and early term									
		infants with									
		respiratory distress.									
21/NI/0009	278082	Accuracy of ECG-guided tip placement and point of care			04/02/2021	27/01/2021					
		ultrasound scan (POC-US) during central line insertion in									
		neonates – a feasibility study									
		CLIN study									
20/LO/0745	273024	Phase 1 / 2 Multicenter Study of the Safety,			09/03/2021	09/06/2020	30/03/2021	31/03/2021		07/04/2021	
		Pharmacokinetics, and Preliminary Efficacy of APL-101 in									
		Subjects with Non-Small Cell Lung Cancer with c-Met EXON									
		14 Skip Mutations and c-Met Dysregulation Advanced Solid									
		Tumors									
20/EE/0204	287569	A PHASE II, MULTICENTER, OPEN-LABEL, SINGLE ARM		24/08/2020	24/08/2020		04/11/2020	24/11/2020		25/11/2020	Neither
		STUDY TO EVALUATE THE PHARMACODYNAMIC									
		EFFECTS OF ONCE WEEKLY ADMINISTRATION OF									
		GANTENERUMAB IN PARTICIPANTS WITH EARLY									
		(PRODROMAL TO MILD) ALZHEIMER'S DISEASE									
20/NW/0312	284188	A Registry-based, Randomised, Double-blind, Placebo-		22/10/2020	29/03/2021	23/07/2020					
		Controlled Cardiovascular Outcomes Trial to Evaluate the									
		Effect of Dapagliflozin on the Incidence of Heart									
		Failure or Cardiovascular Death in Patients without Diabetes									
		with Acute Myocardial Infarction at Increased Risk for									
		Subsequent Development of Heart Failure.									
20/LO/1283	285961	A randomised phase 3 double-blind, placebo-controlled trial		01/12/2020	01/12/2020						Neither
20/20/1200	200001	of adding darolutamide to androgen deprivation therapy and		01/12/2020	01/12/2020						
		definitive or salvage radiation in very high risk, clinically									
		localised prostate cance									
20/WM/0221	285758	LumenEye during CovID-19 (LuCID study)			05/02/2021	10/09/2020					
20/HRA/3414		, , , , , , , , , , , , , , , , , , , ,	09/10/2020		14/09/2020	19/08/2020		05/10/2020		05/40/2020	
20/HRA/3414	204190	Investigating the relationship between the renin angiotensin	09/10/2020		14/09/2020	19/06/2020		05/10/2020		05/10/2020	
20/NU/2022	4000004	system and the coagulopathy associated with COVID-19		05/44/0000	05/44/0000						Naith ar
20/NI/0086	1003261	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-		25/11/2020	25/11/2020						Neither
		CONTROLLED, MULTI-CENTER STUDY TO EVALUATE									
		THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN									
		PATIENTS WITH ISN/RPS 2003 CLASS III OR IV LUPUS	1								
		NEPHRITIS									
20/WM/0115	278915	Solitaireâ,,¢ With the Intention For Thrombectomy Plus			08/04/2020			Site of	declined to particip	ate)	
		Intravenous t-PA Versus DIRECT Solitaireâ,,¢ Stent-retriever									
		Thrombectomy in Acute Anterior Circulation Stroke									

20/EM/0115	282431	A randomised phase II proof of principle multi-arm multi- stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection	29/09/2020	03/06/2020	05/06/2020		26/06/2020	26/06/2020	26/06/2020	Neither
19/NE/0110	257719	A randomised, double-blind, placebo-controlled, cross-over trial of zibotentan in microvascular angina		28/05/2020	08/07/2020	04/12/2019	16/12/2020	04/01/2021	05/01/2021	Sponsor
20/NE/0169	279315	A first-in-human clinical trial to assess the safety and immunogenicity of a self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19 - COVAC1	19/06/2020		08/06/2020	11/06/2020		16/06/2020		
20/LO/0906	1003020	A Phase 2b, open-label, single-arm study of ZW25 monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers		06/04/2020	09/03/2021		08/12/2020	14/04/2021		
20/LO/1001	282291	A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors	16/12/2020	23/04/2020	26/10/2020	23/10/2020	19/11/2020	08/12/2020	08/12/2020	
20/LO/1070	279091	What is the impact of a modified Roux-en-Y-gastric bypass operation on people with type 2 diabetes mellitus? The LONG LIMB-2 double-blinded randomised controlled clinical trial	01/03/2021	04/11/2020	16/11/2020			01/02/2021	01/02/2021	Neither
20/EM/0036	278520	A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemia.		24/03/2020	06/07/2020		30/06/2020	20/07/2020	03/11/2020	Neither
20/NW/0230	278525	A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an anti-PD-1 antibody, in Combination with Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) Versus BCG (Induction and Maintenance) in Participants with High-Risk, BCG-NaÃ ⁻ ve Non-Muscle Invasive Bladder Cancer		27/04/2020	20/01/2021	18/06/2020	15/02/2021	25/02/2021	12/03/2021	Neither
20/LO/0856	1003178	A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009)		01/04/2020	28/09/2020	18/09/2020	30/11/2020	18/12/2020	23/12/2020	Neither
20/SC/0201	282769	A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients		12/05/2020	12/05/2020			Site d	eclined to participate)	
19/NE/0260	265062	An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy	01/10/2020		08/06/2020		03/07/2020	16/07/2020	17/09/2020	Neither
20/LO/1008	285155	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH).		11/05/2020	27/01/2021	23/11/2020				

00/00/0074	000000	A DUAGE III DANDOMIZED DOUBLE BUILD BUAGES	T	0.4/00/0000	40/44/0000	1			1		N1 - 20
	286893	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA		04/09/2020	12/11/2020						Neither
20/NW/0189		Clinical Evaluation of the LOIS Smartband in patients undergoing elective ICD implantation with defibrillation threshold testing	01/03/2021		23/09/2020		14/12/2020	14/12/2020			Neither
20/SC/0211	282109	Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)	07/07/2020	01/05/2020	13/05/2020			22/05/2020		02/07/2020	
20/HRA/2068	283394	A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome		01/05/2020	01/05/2020		29/05/2020	21/05/2020		29/05/2020	Neither
19/WA/0197	256241	WHiTE 9- BeST: World Hip Trauma Evaluation 9; Blood Cell Salvage Trial. A multi centre randomised controlled trial comparing intra operative cell salvage with standard care in the treatment of hip fractures.		23/04/2020	31/08/2020	02/09/2019					Neither
20/EE/0118	283014	A phase III prospective, interventional, cohort, superiority study to evaluate the benefit of rapid COVID-19 genomic sequencing (the COVID-19 GENOMICS UK project) on infection control in preventing the spread of the virus in United Kingdom NHS hospitals	04/11/2020	23/04/2020	21/09/2020		16/10/2020	28/10/2020		04/11/2020	
20/EM/0087	274214	An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas.		01/04/2020	05/03/2021	19/05/2020	28/01/2021				
19/LO/0288	235544	A Randomised Placebo-Controlled Trial on the effectiveness of Escitalopram and Nortriptyline for depressive symptoms in Parkinson's disease		03/09/2020	28/01/2021	09/07/2020					
	282475	Single-use Point-of-care cArtridge-based RT-PCR Testing of Adults with suspected COVID-19, from Upper airway Samples – a clinical validation study			08/04/2020				declined to partici	pate)	
20/NW/0181	238013	A PHASE 2, 12-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)		07/04/2020	17/11/2020		04/02/2021	12/04/2021			Sponsor

20/WM/0123	282099	A randomized, double-blind, placebo-controlled, multi-centre study to evaluate the safety and efficacy of tocilizumab in	4/2020 31/03/	2020 07/	/04/2020	06/04/2020	15/04/2020	15/04/2020	17/04/2020	
		patients with severe COVID-19 pneumonia								
20/EE/0078	267074	A Phase 3 multicentre, double-blind, randomized, placebo- controlled study to evaluate the efficacy, safety, and tolerability of Rozanolixizumab in adult study participants with persistent or chronic primary immune thrombocytopenia (ITP)- TP0003	20/03/	2020 03/	/11/2020					Neither NHS Trust nor Sponsor
20/SC/0145	281259	A phase I/II trial of a candidate COVID-19 vaccine (COV001) 22/04	4/2020 24/03/	2020 17/	/04/2020	26/03/2020	20/04/2020	20/04/2020	20/04/2020	
18/WM/0270		Multicentre, Open-label Randomised Trial of Superficial Wound Drain on Surgical Site Infection in high Body Mass Index (BMI) Kidney Transplants Recipients.		2020 05/			25/11/2020	30/11/2020		Neither
19/EE/0042	257583	A PHASE III, MULTINATIONAL, MULTICENTER, INVESTIGATOR-MASKED, RANDOMISED, ACTIVE-CONTROLLED TRIAL, COMPARING THE EFFICACY AND SAFETY OF DE-130A WITH XALATAN® IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION OVER A 3-MONTH PERIOD, FOLLOWED BY A 12-MONTH FOLLOW-UP WITH OPEN-LABEL DE-130A TREATMENT.	05/03/	2020 08/	/09/2020	12/04/2019	13/08/2020	06/10/2020	04/11/2020	Neither
20/SC/0085	272571	Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy.	16/01/	2020 01/	/06/2020	17/07/2020	12/04/2021	13/04/2021		Sponsor
18/EE/0389	235758	Seizure PRophylaxis IN Glioma	21/02/	2020 11/	/09/2020		24/03/2021			Neither
20/LO/0197	277125	An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies	18/02/	2020 23/	/07/2020	27/03/2020	10/10/2020	20/10/2020	17/11/2020	Neither
20/NW/0177	1003027	Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205	13/07/	2020 22/	/07/2020		23/12/2020	23/12/2020	23/12/2020	Neither
20/LO/0411	278196	A randomised, placebo controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of a continuous subcutaneous infusion of G3215 in adult subjects	10/09/	2020 10/	/09/2020		28/09/2020	29/09/2020	29/10/2020	Neither
20/NE/0014	272055	Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms in Kawasaki disease	20/02/	2020 14/	/12/2020					Sponsor

			•	•	•						
19/LO/1898	275312	A Phase 2b/3, Double-Blind, Randomised, Placebo-Controlled 48-week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD)		10/02/2020	24/08/2020		15/10/2020	12/01/2021			Neither
19/WA/0358	271728	Pre-Hospital Zone 1 Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for injured patients with exsanguinating sub-diaphragmatic haemorrhage.		23/01/2020	17/06/2020		17/06/2020	26/06/2020	26/	/06/2020	Neither
20/WS/0057	277361	Erythropoietin and Darbepoetin in Neonatal Encephalopathy (EDEN) Trial		01/06/2020	30/03/2021	27/05/2020					
19LO1183	269900	IPX203-B16-03		01/06/2020	17/12/2020	11/10/2019	02/02/2021	02/02/2021			Neither
20/LO/0355	275910	A Physiological Study of the Effect of Î'lpha-MSH on Glucose Clearance and Insulin Sensitivity in Healthy Participants		25/08/2020	10/09/2020	20/05/2020		20/10/2020	20/	/10/2020	Neither
20/YH/0090	278137	AN OPEN-LABEL, MULTICENTER, ROLLOVER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF LONG-TERM ADMINISTRATION OF GANTENERUMAB IN PARTICIPANTS WITH ALZHEIMER'S DISEASE	27/08/2020	21/02/2020	05/05/2020		10/08/2020	13/08/2020	17/	/08/2020	Neither
20/EE/0031	275993	Multicenter, randomized, placebo-controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute noncardioembolic ischemic stroke		20/12/2019	23/07/2020		23/09/2020	28/10/2020	03/	/11/2020	Neither
	274161	Minimally Invasive Realtime Assessment of Continuous Lactate in Exercise (MIRACLE)		10/02/2020	02/11/2020	07/05/2020		15/02/2021			Neither
20/LO/0477	254910	Psychology of pregnancy of unknown location (SOUL)	02/12/2020	06/02/2020	26/10/2020	23/07/2020	02/11/2020	30/11/2020	30/	/11/2020	
20/LO/0068	274808	Pre-conception interventions to reduce blood pressure before pregnancy	02/11/2020	09/10/2020	15/10/2020			30/10/2020	02/	/11/2020	Neither
18/WS/0218	252602	An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastat as adjunctive therapy in pulmonary arterial hypertension (PAH)		25/10/2019	20/11/2020	25/09/2019	26/06/2020	09/12/2020	09/	/12/2020	Neither
19/LO/0329	252963	A randomised, blinded, controlled, Phase 2a study to evaluate the safety and efficacy of administering Regadenoson to patients with critical injury and signs of haemorrhagic shock		07/10/2019	14/08/2020	02/10/2019	07/10/2019	14/08/2020			Sponsor
20/WA/0016	265499	Using Ultrasound 2D Strain Speckle Tracking, 2D Shear Wave Elastography and Transonic flowmeter as Diagnostic and Potential Predictor Tool for Arteriovenous Fistula Outcomes with End Stage Renal Failure.		08/10/2019	10/12/2020	02/03/2020					Neither
19/SC/0634	252084	TREAT Treating severe paediatric asthma; a randomised controlled trial of mepolizumab and omalizumab		04/05/2020	27/08/2020	04/08/2020					Neither
19/LO/1756	272037	A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma/ CA209-9DW		12/09/2019	01/05/2020	30/06/2020	25/03/2020	05/10/2020	15/	/10/2020	Neither
19/SW/0043	235625	CHIEF-PD.		11/09/2019	18/03/2021	26/06/2019		08/04/2021			
20/LO/0031	266400	Perinatal and 2 year neurodevelopmental outcome in late preterm fetal compromise: the TRUFFLE 2 Randomised Trial	08/10/2020	14/02/2020	18/09/2020	04/02/2020		01/10/2020	02/	/10/2020	
									•		

20/SC/0081	265850	Feasibility of identifying autonomic drivers for human Atrial Fibrillation		19/02/2020	03/06/2020	21/04/2020	24/02/2020	27/07/2020	27/07/2020	Neither
19/LO/1449	269837	Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced/Unresectable Biliary Tract Carcinoma		04/07/2019	05/10/2020	24/03/2020	10/11/2020	26/11/2020	13/01/2021	Sponsor
	262552	Phase 1/1b Study of Intratumorally Administered STING Agonist E7766 in Subjects With Advanced Solid Tumors or Lymphomas			04/05/2020	03/07/2020	13/09/2020	15/09/2020		Neither
20/NW/0054	274432	Placebo-controlled Trial of Pembrolizumab in Esophageal Carcinoma Participants Receiving Concurrent dCRT - MK3475 Keynote 975	01/12/2020	07/11/2019	18/06/2020	31/03/2020	07/11/2019	13/08/2020		Neither
19/LO/0855	260338	A Phase 2, randomized, non-comparative, open-label study of NKTR-214 in combination with nivolumab and of chemotherapy in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients with low PD L1 expression		03/05/2019	28/05/2020	27/06/2019				Sponsor
19/LO/1152	265415	A phase 2, open-label, single-arm, multicenter study to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancy harboring activating FGFR mutations and translocations		02/05/2019	22/10/2020	16/08/2019	22/11/2019			Sponsor
20/LO/0474	266759	Psilocybin as a Treatment for Restrictive Anorexia Nervosa: A Pilot Study			11/01/2021	23/06/2020	12/04/2021	12/04/2021	12/04/2021	Neither
19/LO/1393	266410	Embotrap extraction & clot evaluation & lesion evaluation for neurothrombectomy	03/02/2021	07/05/2019	17/06/2020	17/11/2019	27/07/2020	18/01/2021		NHS Provider
19/SC/0583	258210	Non invasive optic techniques in neurosurgery			18/09/2020			13/11/2020		Sponsor
20/LO/0938		A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible		07/10/2019	09/03/2021	13/11/2020	02/11/2020			
	226984	Defining personalised outcomes in pre-school children with recurrent wheeze			24/02/2021	31/05/2019				
	259170	Singing for Health: Improving Experience of Lung Disease (SHIELD)			24/11/2020	23/05/2019	07/02/2019	16/12/2020		Neither
	243809	Randomised controlled trial to compare tissue reactions and scarring with polypropylene vs polyglactin 910 sutures in periocular skin			21/05/2020	07/04/2020				Neither
19/LO/0063	255904	A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION		24/04/2020	01/06/2020					Neither

20/LO/0345 2	A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by Cardiopulmonary Exercise Testing in Subjects with World Health Organization Group 1 Pulmonary Hypertension Who Recently Initiated Therapy (ADVANCE Capacity)	25/02/2020	31/03/2021			
19/LO/0062 2	A study evaluating the efficacy and safety of ralinepag to improve treatment outcomes in PAH patients.	24/04/2020	17/06/2020			Neither